Más difícil todavía: tratar una glomerulonefritis rápidamente progresiva grave en el seno de una neumonía por COVID-19

Martín Navarro, Juan A; Cintra Cabrera, Melissa; Lucca Proccacini, Fabio; Muñoz Rodríguez, Jorge; Roldán Cortés, David; Lucena Valverde, Rafael; Ortega Díaz, Mayra; Puerta Carretero, Marta; Gil Herrera, Juana; Jaldo Rodríguez, Maria Teresa.
Nefrología (Madrid) ; 42(1): 1-5, Ene-Feb., 2022. ilus, tab
Artículo en Español | IBECS (España) | ID: ibc-204279

Documentos relacionados

  1. [Anti-glomerular basement membrane disease].
  2. Predictors of Kidney Outcomes of Anti-Glomerular Basement Membrane Disease in a Large Chinese Cohort.
  3. Endopeptidase Therapy for Anti-Glomerular Basement Membrane Disease: Beware of Anti-Hinge Antibodies!
  4. Efficacy of rituximab for patients with anti-glomerular basement membrane disease.
  5. Anti-Glomerular Basement Membrane Disease: Broadening the Spectrum.
  6. Difficulties in Goodpasture's syndrome diagnosing.
  7. Authors' Reply: Endopeptidase Therapy for Anti-Glomerular Basement Membrane Disease: Beware of Anti-Hinge Antibodies!
  8. The treatment of ANCA-associated rapidly-progressive glomerulonephritis and Goodpasture syndrome with therapeutic apheresis.
  9. Diagnostic and management challenges in Goodpasture's (anti-glomerular basement membrane) disease.
  10. Autoimmunity in Anti-Glomerular Basement Membrane Disease: A Review of Mechanisms and Prospects for Immunotherapy.